R&D Bases

Chugai is promoting R&D based on organic collaboration between the respective functions of its three core research laboratories in Japan: Fuji Gotemba (Gotemba City, Shizuoka Prefecture), Kamakura (Kamakura City, Kanagawa Prefecture) and Ukima (Kita-ku, Tokyo). Moreover, Chugai is utilizing the Roche Group’s network to expand its drug research structure globally in a variety of fields, making it possible to discover promising new drug candidates early and to shorten development time.

Research Bases

Fuji Gotemba Research Laboratories
We conduct drug discovery research of treatments for bone and joint, renal, hematologic and immune diseases based on antibody engineering, developmental engineering, protein engineering and chemical synthesis research. Our development research involves safety, pharmacokinetics and formulations, and we also conduct clinical pharmaceutical research.
Kamakura Research Laboratories
We conduct drug discovery research of cancer treatments based on chemical synthesis, protein engineering and bioinformatics. We also conduct high-throughput screening of chemical agents, pharmacokinetics research, and clinical pharmaceutical research.
Ukima Research Laboratories
As a facility focused on industrialization of newly developed drug candidates, we conduct pharmaceutical API manufacturing process research, product design (formulation and packaging) and production method research, facility design and production technology research, analysis of the structure and physical properties of pharmaceuticals, and quality testing methods.

Satellite Labs

Chugai has set up satellite labs to shorten drug discovery and development time and to continuously create innovative R&D projects.

Chugai Pharmabody Research Pte. Ltd. (Singapore)

Chugai Pharmabody Research utilizes Chugai’s proprietary antibody engineering technologies to quickly and efficiently generate innovative therapeutic antibody candidates that provide unprecedented value.

Collaboration Laboratory sited at IFReC

A comprehensive collaboration for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Chugai was made in May 2016. Based on the collaboration, Joint Research Chair of Innovative Drug Discovery in Immunology has been set up at IFReC. Exploratory research for drug discovery is being conducted through synergy between IFReC’s latest research results and Chugai’s proprietary antibody engineering technologies.

Click here for more information on Comprehensive Collaboration Agreement between IFReC.

IFReC website:

Collaboration Laboratory sited at National Cancer Center Research Institute

Search for new CIT targets through immune cell profiling of cancer microenvironment

National Cancer Center Research Institute website:

Collaboration Laboratory sited at the University of Tokyo Center of Innovation (COI)

Search for new targets in rheumatic diseases through GWAS/eQTL Analysis

The University of Tokyo COI website:

  • Genome wide association study (GWAS): Research approach to identify association of genotypes with phenotypes of diseases by testing for differences in the allele frequency of genetic variants
  • eQTL: A locus that explains a fraction of the genetic variance of a gene expression phenotype
  • Like
  • Tweet
  • LINE it!
  • E-mail


Back to top